Back to Search
Start Over
Developmental strategy for a new Group A meningococcal conjugate vaccine (MenAfriVacR)
- Source :
- Human Vaccines & Immunotherapeutics; May 2018, Vol. 14 Issue: 5 p1103-1106, 4p
- Publication Year :
- 2018
-
Abstract
- ABSTRACTUntil recently, periodic Group A meningococcal meningitis outbreaks were a major public health problem in the sub-Saharan Africa. In 2001, the Meningitis Vaccine Project (MVP), a partnership between the World Health Organization (WHO) and PATH, a Seattle-based NGO, and the Serum Institute of India Pvt Ltd (SIIPL) initiated discussions aimed at establishing a collaboration to develop a Group A meningococcal conjugate vaccine for this unmet medical need. Over the next 8 years the partnership made countless strategic decisions about product characteristics, raw materials, potential target populations, geographic prioritization and affordability of the vaccine to name a few. These decisions evolved into detailed plans for preclinical development, extensive field trials in Africa and India and a focused regulatory strategy specific for the Men A conjugate vaccine. Important characteristics of the process included, flexibility, transparency andeffective partnerships that included public agencies as well as private companies in Africa, Europe, the United States and India.
Details
- Language :
- English
- ISSN :
- 21645515 and 2164554X
- Volume :
- 14
- Issue :
- 5
- Database :
- Supplemental Index
- Journal :
- Human Vaccines & Immunotherapeutics
- Publication Type :
- Periodical
- Accession number :
- ejs45728844
- Full Text :
- https://doi.org/10.1080/21645515.2017.1391434